Schrodinger (SDGR) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
UroGen Pharma (URGN) has outperformed Schrodinger (SDGR) over the past year, gaining 141.7% versus a gain of 35.4%. Over five years, URGN leads with a +139.1% price change compared with -50.7% for SDGR. Schrodinger is the larger company by market cap ($1.95 billion vs $1.73 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SDGR | URGN |
|---|---|---|
| Share price | $26.06 | $35.48 |
| Market cap | $1.95B | $1.73B |
| 1-day change | -4.52% | -12.83% |
| YTD return | +52.63% | +73.78% |
| 1-year return | +35.37% | +141.69% |
| 5-year return | -50.70% | +139.13% |
| Forward P/E | — | 12.70 |
| EPS (TTM) | $-0.74 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.78 | $50.81 |
| 52-week low | $10.95 | $15.86 |
| Distance from 52-week high | -22.86% | -30.17% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -17.76% | +69.11% |
| Average volume | 1.74M | 827.16K |
| Shares outstanding | 65.64M | 48.88M |
| Employees | 850 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed SDGR by 106.3 percentage points over the past year.
About Schrodinger
SDGR stock →Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Health Care · Biotechnology: Pharmaceutical Preparations · 850 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
SDGR vs URGN FAQ
Which is bigger, Schrodinger or UroGen Pharma?
Schrodinger (SDGR) is larger, with a market capitalization of $1.95B compared with $1.73B for UroGen Pharma (URGN).
Which stock has performed better over the past year, SDGR or URGN?
URGN returned +141.69% over the past 12 months, compared with +35.37% for SDGR (price return, excluding dividends). Past performance does not predict future results.
Are Schrodinger and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.